1. Home
  2. PHGE vs AEMD Comparison

PHGE vs AEMD Comparison

Compare PHGE & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$0.17

Market Cap

2.0M

Sector

Health Care

ML Signal

HOLD

Logo Aethlon Medical Inc.

AEMD

Aethlon Medical Inc.

HOLD

Current Price

$3.11

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHGE
AEMD
Founded
2015
1984
Country
United States
United States
Employees
20
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
2.1M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
PHGE
AEMD
Price
$0.17
$3.11
Analyst Decision
Hold
Hold
Analyst Count
1
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
994.1K
139.0K
Earning Date
05-15-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.51
52 Week High
$8.50
$5.89

Technical Indicators

Market Signals
Indicator
PHGE
AEMD
Relative Strength Index (RSI) 25.21 76.84
Support Level N/A $2.00
Resistance Level $0.21 $3.22
Average True Range (ATR) 0.02 0.16
MACD 0.02 0.35
Stochastic Oscillator 41.52 77.37

Price Performance

Historical Comparison
PHGE
AEMD

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.

About AEMD Aethlon Medical Inc.

Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.

Share on Social Networks: